Brar S, Ganesh S, Reddy SS, et al. - Researchers conducted this prospective, randomized, comparison study to compare the safety and effectiveness of 0.1% riboflavin in two different solutions which are used in corneal collagen crosslinking (CXL) for the treatment of keratoconus. Participants in the study were 61 patients (100 eyes) with progressive keratoconus who had CXL with riboflavin 0.1% solution as a photosensitizer, using the standard Dresden protocol of using 3mW/cm ² UV-A irradiation for 30 minutes which corresponds to a total energy of 5.4 J/cm ². Both riboflavin solutions were equally safe and effective in the treatment of progressive keratoconus, resulting in comparable changes in mean manifest spherical equivalent, astigmatism, best-corrected distance visual acuity, keratometry values, thinnest pachymetry values, demarcation line depth, and endothelial cell density at 12 months postoperatively.